The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol

Int J Mol Sci. 2023 Apr 9;24(8):6959. doi: 10.3390/ijms24086959.

Abstract

Asthma is a heterogeneous inflammatory disease characterized by abnormalities in immune response. Due to the inherent complexity of the disease and the presence of comorbidities, asthma control is often difficult to obtain. In asthmatic patients, an increased prevalence of irregular menstrual cycles, infertility, obesity, and insulin resistance has been reported. Given that these conditions are also common in patients with polycystic ovary syndrome (PCOS), we propose the definition of "asthma-PCOS overlap syndrome" to indicate a medical condition which shares characteristics of both diseases. The aim of this review is to analyze the links between asthma and PCOS and evaluate the therapeutic role of myo-inositol, a natural compound currently utilized in patients with PCOS, in the management of asthma patients.

Keywords: asthma; infertility; inflammation; myo-inositol; obesity; polycystic ovary syndrome; premenstrual asthma; α-lactalbumin.

Publication types

  • Review

MeSH terms

  • Asthma* / drug therapy
  • Female
  • Humans
  • Inositol / therapeutic use
  • Insulin Resistance*
  • Polycystic Ovary Syndrome* / drug therapy

Substances

  • Inositol

Grants and funding

This research received no external funding.